Summary — S.1586: “An Act relative to smoking cessation agents” (Massachusetts)
Source and sponsors
- Filed in the Massachusetts Senate (Senate Docket No. 99). Presented by Sen. Michael O. Moore (Second Worcester).
- Note: the materials provided also include unrelated/contradictory headings (an “App Store Accountability Act” and an unrelated list of federal sponsors). This summary focuses on the Massachusetts bill text titled “An Act relative to smoking cessation agents.”
Purpose and intent
- To expand the ability of licensed pharmacists to dispense smoking‑cessation medications under standardized, physician‑developed protocols, with training and regulatory oversight — increasing timely access to treatment intended to help patients quit tobacco use.
Key provisions
- Addition of a new Section 19G to Chapter 94C of the Massachusetts General Laws.
- Pharmacist dispensing authority:
- A licensed pharmacist may dispense “Smoking Cessation Agents” pursuant to written, standardized procedures or protocols created by an actively practicing physician who is registered with the commissioner to distribute/dispense controlled substances (per section 7).
- Protocols must be filed at the pharmacist’s place of practice and with the Board of Registration in Pharmacy before they are used.
- Training requirement:
- Pharmacists must complete a commissioner‑approved training program before dispensing under this section. Required training topics include documentation, quality assurance, referral to additional services, and recommending patient follow‑up with a medical practitioner.
- Rulemaking:
- The Department of Public Health, the Board of Registration in Medicine, and the Board of Registration in Pharmacy are directed to adopt regulations to implement the section.
Who and what would be affected
- Pharmacists: new authority and responsibilities (protocol filing, training, documentation, referrals).
- Physicians: responsible for developing standardized protocols used by pharmacists.
- Patients seeking smoking‑cessation treatment: likely improved access to medications and counseling via pharmacies.
- Regulatory agencies: DPH and professional boards will need to promulgate implementing rules and oversight processes.
Procedural status and timeline (from provided actions)
- Filed: 01/07/2025 (Senate Docket No. 99).
- Subsequent actions include referrals to committees (Public Health; Commerce, Science & Transportation; Judiciary), hearings scheduled (e.g., 07/14/2025), review by the Attorney General for opinion, and committee reporting favorably and referral to Health Care Financing. Current listed status: “OPINION REFERRED TO JUDICIARY.” (The provided action list contains duplicate and conflicting entries.)
Notes and considerations
- The bill text does not define “Smoking Cessation Agents” in the excerpt provided; scope (e.g., nicotine replacement therapies, prescription agents such as bupropion or varenicline, or other medications) will affect clinical and regulatory implementation.
- The requirement that physician protocols be created by a physician registered to dispense controlled substances may influence which agents can be included.
- Implementation depends on timely adoption of regulations and development of approved training programs. Potential impacts include increased access to cessation therapy, shifting some clinical initiation to pharmacies, and administrative/training costs for pharmacies.
